secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001193125-24-235275
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics prices upsized $500M public offering at $50/share; net proceeds ~$472M
--------------------------------------------------------------------------------

- Pricing of 10,000,000 shares of common stock at $50.00/share for gross proceeds of $500.0 million.
- Net proceeds estimated at approximately $472.0 million (or ~$542.9 million if 1.5M share option exercised).
- Underwriters granted 30-day option to purchase up to 1,500,000 additional shares; closing expected October 10, 2024.
- Proceeds to fund R&D of clinical-stage candidates, pre-commercialization activities, and general corporate purposes.
- Leerink Partners and Morgan Stanley acting as joint bookrunning managers for the offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524235275/0001193125-24-235275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524235275/d857933d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-235275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer